Cargando…

The HDAC7–TET2 epigenetic axis is essential during early B lymphocyte development

Correct B cell identity at each stage of cellular differentiation during B lymphocyte development is critically dependent on a tightly controlled epigenomic landscape. We previously identified HDAC7 as an essential regulator of early B cell development and its absence leads to a drastic block at the...

Descripción completa

Detalles Bibliográficos
Autores principales: Azagra, Alba, Meler, Ainara, de Barrios, Oriol, Tomás-Daza, Laureano, Collazo, Olga, Monterde, Beatriz, Obiols, Mireia, Rovirosa, Llorenç, Vila-Casadesús, Maria, Cabrera-Pasadas, Mónica, Gusi-Vives, Mar, Graf, Thomas, Varela, Ignacio, Sardina, José Luis, Javierre, Biola M, Parra, Maribel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410891/
https://www.ncbi.nlm.nih.gov/pubmed/35904805
http://dx.doi.org/10.1093/nar/gkac619
Descripción
Sumario:Correct B cell identity at each stage of cellular differentiation during B lymphocyte development is critically dependent on a tightly controlled epigenomic landscape. We previously identified HDAC7 as an essential regulator of early B cell development and its absence leads to a drastic block at the pro-B to pre-B cell transition. More recently, we demonstrated that HDAC7 loss in pro-B-ALL in infants associates with a worse prognosis. Here we delineate the molecular mechanisms by which HDAC7 modulates early B cell development. We find that HDAC7 deficiency drives global chromatin de-condensation, histone marks deposition and deregulates other epigenetic regulators and mobile elements. Specifically, the absence of HDAC7 induces TET2 expression, which promotes DNA 5-hydroxymethylation and chromatin de-condensation. HDAC7 deficiency also results in the aberrant expression of microRNAs and LINE-1 transposable elements. These findings shed light on the mechanisms by which HDAC7 loss or misregulation may lead to B cell–based hematological malignancies.